-
Research Progress in Signaling Pathway and Related Drugs of Target GDF15
Xiaonisha/PharmaSources
April 19, 2023
GDF15 being a kind of endocrine hormone and a member of transforming growth factor β superfamily, acts as an autocrine regulatory molecule in macrophages, which was identified and found from the clone of activated macrophage cell line.
-
Recent Progress of Pharmaceutical Industry
Lin Zhang
November 22, 2021
2021 has been a wild year for the world, and the pharmaceutical industry as well. There have been significant developments in the past few months that have changed the state of the industry...
-
Advancing oncology
Sarah Harding
March 18, 2021
With so much going on last year, you might be forgiven if you missed a ground-breaking announcement in November 2020 about the ‘Galleri blood test’.
-
The tumor disappears after infection with coronavirus! Looking at the “killing cancer with the virus” concept in the oncology field
PharmaSources/Wang Hong
January 21, 2021
The world is full of wonders. According to an article published by a British doctor in the British Journal of Haematology two days ago, a malignant lymphoma patient’s tumor almost disappeared after infection with coronavirus!
-
Pharmaceutical News of the Week (July. 20th-July. 24th) | PharmaSources.com - Updates on Performance,Volumn-based Procurement and Others
PharmaSources/Caicai
July 29, 2020
The hottest event of the week was the official kick-off of the centralized procurement of the third batch of pharmaceutical products organized in China, with 86 specifications started to be acquired the basic information.
-
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
ACN Newswire
August 02, 2025
Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash.
-
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ
PR Newswire
July 29, 2025
Alphamab Oncology announced that anti-HER2 biparatopic antibody-drug conjugate JSKN003 has been granted Orphan Drug Designation by the FDA for the treatment of gastric cancer and gastroesophageal junction cancer (GC/GEJ).
-
AXA and Prosper Health introduce pioneering dedicated cancer case management service in Greater Bay Area[1]
PharmaSources
January 22, 2025
AXA Hong Kong and Macau partners with Prosper Health to launch the Greater Bay Area Cancer Medical Concierge Service Network for eligible customers, integrating resources to meet cross - border medical demands.
-
BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy
PharmaSources
January 14, 2025
German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid tumors
-
Olympus Launches New 4K Camera Head for Urological Endoscopy
PharmaSources
September 24, 2024
Unified Visualization with True 4K Imaging and 4K Narrow Band Imaging as well as blue light observation
ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
